Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet

Inclusion Criteria: Type-2 diabetes, defined as: * Age at onset of diabetes ≥ 40 years * Fasting serum C-peptide ≥ 300 pmol/l or a non-fasting or glucagon-stimulated serum C-peptide ≥ 600 pmol/l * No history of ketonuria or ketoacidosis. * BMI ≤ 27 kg/m2. * Fasting plasma-glucose ≥ 6.5 mmol/l after at least one month of diet-only treatment. * HbA1c ≤ 9.5% at ongoing oral anti-hyperglycaemic agents. HbA1c ≥ 6.5% after minimum one month of diet-only treatment. * Weight-loss of no more than 5.0 kg during the last 6 months prior to enrolment. Exclusion Criteria: * Type-1 diabetes * Insulin-treated type-2 diabetes * Secondary diabetes, heart-failure * Serum-creatinine above the upper limit * Serum-ASAT elevated more than 3 fold above the upper limit * Factor II-VII-X decreased below 0.7 * Ongoing coexisting illnesses with a life-shortening prognosis * Mental retardation or reduced intellectual behaviour * Pregnancy * History of drug-abuse or HbA1c\>10.5% at two separate visits with at least one month interval during treatment-periods.